BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 29945674)

  • 1. Treatment of voluminous and complicated superficial slow-flow vascular malformations with sirolimus (PERFORMUS): protocol for a multicenter phase 2 trial with a randomized observational-phase design.
    Maruani A; Boccara O; Bessis D; Guibaud L; Vabres P; Mazereeuw-Hautier J; Barbarot S; Chiaverini C; Blaise S; Droitcourt C; Mallet S; Martin L; Lorette G; Woillard JB; Jonville-Bera AP; Rollin J; Gruel Y; Herbreteau D; Goga D; le Touze A; Leducq S; Gissot V; Morel B; Tavernier E; Giraudeau B;
    Trials; 2018 Jun; 19(1):340. PubMed ID: 29945674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sirolimus (Rapamycin) for Slow-Flow Malformations in Children: The Observational-Phase Randomized Clinical PERFORMUS Trial.
    Maruani A; Tavernier E; Boccara O; Mazereeuw-Hautier J; Leducq S; Bessis D; Guibaud L; Vabres P; Carmignac V; Mallet S; Barbarot S; Chiaverini C; Droitcourt C; Bursztejn AC; Lengellé C; Woillard JB; Herbreteau D; Le Touze A; Joly A; Léauté-Labrèze C; Powell J; Bourgoin H; Gissot V; Giraudeau B; Morel B
    JAMA Dermatol; 2021 Nov; 157(11):1289-1298. PubMed ID: 34524406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial.
    Leducq S; Caille A; Barbarot S; Bénéton N; Bessis D; Boccara O; Bursztejn AC; Chiaverini C; Dompmartin A; Droitcourt C; Gissot V; Goga D; Guibaud L; Herbreteau D; Le Touze A; Léauté-Labrèze C; Lorette G; Mallet S; Martin L; Mazereeuw-Hautier J; Phan A; Plantin P; Quéré I; Vabres P; Bourgoin H; Giraudeau B; Maruani A;
    Trials; 2019 Dec; 20(1):739. PubMed ID: 31847908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase II study.
    Hammer J; Seront E; Duez S; Dupont S; Van Damme A; Schmitz S; Hoyoux C; Chopinet C; Clapuyt P; Hammer F; Vikkula M; Boon LM
    Orphanet J Rare Dis; 2018 Oct; 13(1):191. PubMed ID: 30373605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical sirolimus solution for lingual microcystic lymphatic malformations in children and adults (TOPGUN): study protocol for a multicenter, randomized, assessor-blinded, controlled, stepped-wedge clinical trial.
    Marchand A; Caille A; Gissot V; Giraudeau B; Lengelle C; Bourgoin H; Largeau B; Leducq S; Maruani A
    Trials; 2022 Jul; 23(1):557. PubMed ID: 35804404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective multicenter study of sirolimus for complicated vascular anomalies.
    Ji Y; Chen S; Yang K; Zhou J; Zhang X; Jiang X; Xu X; Lu G; Qiu L; Kong F; Zhang Y
    J Vasc Surg; 2021 Nov; 74(5):1673-1681.e3. PubMed ID: 34082006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Benign aggressive vascular anomalies in children].
    Boccara O; Maruani A; Léauté-Labrèze C
    Bull Cancer; 2018 Jun; 105(6):610-625. PubMed ID: 29571951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus for the treatment of children with various complicated vascular anomalies.
    Lackner H; Karastaneva A; Schwinger W; Benesch M; Sovinz P; Seidel M; Sperl D; Lanz S; Haxhija E; Reiterer F; Sorantin E; Urban CE
    Eur J Pediatr; 2015 Dec; 174(12):1579-84. PubMed ID: 26040705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and absorption of topical sirolimus for the treatment of vascular anomalies in children: A case series.
    Le Sage S; David M; Dubois J; Powell J; McCuaig CC; Théorêt Y; Kleiber N
    Pediatr Dermatol; 2018 Jul; 35(4):472-477. PubMed ID: 29790593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus in the Treatment of Vascular Anomalies.
    Triana P; Dore M; Cerezo VN; Cervantes M; Sánchez AV; Ferrero MM; González MD; Lopez-Gutierrez JC
    Eur J Pediatr Surg; 2017 Feb; 27(1):86-90. PubMed ID: 27723921
    [No Abstract]   [Full Text] [Related]  

  • 11. Preliminary results of the European multicentric phase III trial regarding sirolimus in slow-flow vascular malformations.
    Seront E; Van Damme A; Legrand C; Bisdorff-Bresson A; Orcel P; Funck-Brentano T; Sevestre MA; Dompmartin A; Quere I; Brouillard P; Revencu N; De Bortoli M; Hammer F; Clapuyt P; Dumitriu D; Vikkula M; Boon LM
    JCI Insight; 2023 Nov; 8(21):. PubMed ID: 37937645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sirolimus for the treatment of complicated vascular anomalies in children.
    Hammill AM; Wentzel M; Gupta A; Nelson S; Lucky A; Elluru R; Dasgupta R; Azizkhan RG; Adams DM
    Pediatr Blood Cancer; 2011 Dec; 57(6):1018-24. PubMed ID: 21445948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A narrative review of the role of sirolimus in the treatment of congenital vascular malformations.
    Geeurickx M; Labarque V
    J Vasc Surg Venous Lymphat Disord; 2021 Sep; 9(5):1321-1333. PubMed ID: 33737259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study.
    Weiss B; Widemann BC; Wolters P; Dombi E; Vinks AA; Cantor A; Korf B; Perentesis J; Gutmann DH; Schorry E; Packer R; Fisher MJ
    Pediatr Blood Cancer; 2014 Jun; 61(6):982-6. PubMed ID: 24851266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Mammalian Target of Rapamycin Inhibitors in Vascular Anomalies: A Systematic Review.
    Nadal M; Giraudeau B; Tavernier E; Jonville-Bera AP; Lorette G; Maruani A
    Acta Derm Venereol; 2016 May; 96(4):448-52. PubMed ID: 26607948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of sirolimus in the treatment of vascular anomalies: A systematic review.
    Freixo C; Ferreira V; Martins J; Almeida R; Caldeira D; Rosa M; Costa J; Ferreira J
    J Vasc Surg; 2020 Jan; 71(1):318-327. PubMed ID: 31676179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirolimus for the Treatment of a Massive Capillary-Lymphatico-Venous Malformation: A Case Report.
    Vlahovic AM; Vlahovic NS; Haxhija EQ
    Pediatrics; 2015 Aug; 136(2):e513-6. PubMed ID: 26148957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single Center Experience of Sirolimus Therapy in Head and Neck Low-flow Vascular Malformations.
    Pang C; Evans N; Jethwa P; Papadopoulou A; Khalifa M; Tsui J; Hamilton G; Lim CS; Brookes J
    Vasc Endovascular Surg; 2021 Jul; 55(5):482-490. PubMed ID: 33878964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of sirolimus in the treatment of vascular malformations: A protocol for systematic review and meta-analysis.
    Dong J; Han D; Wang D; Lu H; Wang X
    Medicine (Baltimore); 2020 Oct; 99(40):e22596. PubMed ID: 33019479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-center experience with sirolimus therapy for vascular malformations.
    Yesil S; Tanyildiz HG; Bozkurt C; Cakmakci E; Sahin G
    Pediatr Hematol Oncol; 2016 Apr; 33(3):219-25. PubMed ID: 27128161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.